Innate commences dosing in SPMS trial
Innate Immunotherapeutics (ASX:IIL) has commenced dosing in a phase IIb trial of MIS416 in secondary progressive multiple sclerosis (SPMS).
Patient dosing is now underway at the trial’s sites in Perth and Melbourne. A third site in Brisbane is due to commence recruiting patients after tomorrow.
The randomised, double-blind, placebo-controlled trial of the efficacy and safety of MIS416 in Secondary Progressive Multiple Sclerosis (SPMS) aims to recruit up to 90 patients.
The trial is being held at the Western Australian Neuroscience Research Institute, Nucleus Network’s AMREP Centre for Clinical Studies in Melbourne and Brisbane’s Wesley-St Andrew's Research Institute.
Innate also announced it has appointed Dr Claudia Mansell as senior research scientist. Mansell will lead the analysis of trial subjects’ blood samples, with the goal of facilitating the development of the first test that could be used to monitor patients’ clinical responses to MIS416.
Mansell joins Innate from the University of Auckland’s School of Biological Sciences. She has a PhD in immunology from Germany's Heinrich Heine Universität and the Harvard Medical School.
Around 30% of multiple sclerosis sufferers worldwide have SPMS and there are currently no approved drugs for ongoing treatment for the disease. Around 23,000 Australians have MS.
Innate Immunotherapeutics (ASX:IIL) shares were trading 14.71% higher at $0.195 as of around 1 pm on Tuesday.
Brain cells mature faster in space than on Earth
Microgravity is known to alter the muscles, bones, the immune system and cognition, but little is...
Fetuses can fight infections within the womb
A fetus has a functional immune system that is well-equipped to combat infections in its...
Gene therapy reverses heart failure in large animal model
The therapy increases the amount of blood the heart can pump and dramatically improves survival,...
